Jefferies Financial Group Inc. Editas Medicine, Inc. Transaction History

Jefferies Financial Group Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$6.25 - $11.11 $4,812 - $8,554	-770 Reduced 2.98%	25,100 $254,000
Q3 2023 Nov 14, 2023	BUY	$6.92 - $9.31 $5,328 - $7,168	770 Added 3.07%	25,870 $201,000
Q2 2023 Aug 14, 2023	BUY	$6.36 - $11.47 $159,636 - $287,897	25,100 New	25,100 $206,000
Q4 2022 Sep 21, 2023	BUY	$8.32 - $13.21 $658,303 - $1.05 Million	79,123 Added 315.23%	104,223 $924,000
Q4 2022 Feb 14, 2023	BUY	$8.32 - $13.21 $1.05 Million - $1.66 Million	125,921 New	125,921 $1.12 Million

217

48M

637K

292K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $179M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

Stay updated on Jefferies Financial Group Inc. with notifications on news.